PortalPublikationenQuality of life measurement in vitiligo: Position statement ...

Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts

Standard

Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts. / Chernyshov, Pavel V; Tomas-Aragones, Lucia; Manolache, Liana; Pustisek, Nives; Salavastru, Carmen Maria; Marron, Servando E; Bewley, Anthony; Svensson, Ake; Poot, Françoise; Suru, Alina; Salek, Sam S; Augustin, Matthias; Szepietowski, Jacek С; Koumaki, Dimitra; Katoulis, Alexander C; Sampogna, Francesca; Abeni, Damiano; Linder, Dennis Michael; Speeckaert, Reinhart; van Geel, Nanja; Seneschal, Julien; Ezzedine, Khaled; Finlay, Andrew Y.

in: J EUR ACAD DERMATOL, Jahrgang 37, Nr. 1, 01.2023, S. 21-31.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Leitlinie, Empfehlung, Stellungnahme › Forschung › Begutachtung

Harvard

Chernyshov, PV, Tomas-Aragones, L, Manolache, L, Pustisek, N, Salavastru, CM, Marron, SE, Bewley, A, Svensson, A, Poot, F, Suru, A, Salek, SS, Augustin, M, Szepietowski, JС, Koumaki, D, Katoulis, AC, Sampogna, F, Abeni, D, Linder, DM, Speeckaert, R, van Geel, N, Seneschal, J, Ezzedine, K & Finlay, AY 2023, 'Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts', J EUR ACAD DERMATOL, Jg. 37, Nr. 1, S. 21-31. https://doi.org/10.1111/jdv.18593

APA

Chernyshov, P. V., Tomas-Aragones, L., Manolache, L., Pustisek, N., Salavastru, C. M., Marron, S. E., Bewley, A., Svensson, A., Poot, F., Suru, A., Salek, S. S., Augustin, M., Szepietowski, J. С., Koumaki, D., Katoulis, A. C., Sampogna, F., Abeni, D., Linder, D. M., Speeckaert, R., ... Finlay, A. Y. (2023). Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts. J EUR ACAD DERMATOL, 37(1), 21-31. https://doi.org/10.1111/jdv.18593

Vancouver

Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE et al. Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts. J EUR ACAD DERMATOL. 2023 Jan;37(1):21-31. https://doi.org/10.1111/jdv.18593

Bibtex

@article{6c8baaa68d584ec391fba13b07c52a43,
title = "Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts",
abstract = "Members of the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient Oriented Outcomes reviewed the instruments available for health-related (HR) QoL assessment in vitiligo and together with external vitiligo experts (including representatives of the EADV Vitiligo Task Force) have made practical recommendations concerning the assessment of QoL in vitiligo patients. The Dermatology Life Quality Index (DLQI) was the most frequently used HRQoL instrument, making comparison of results between different countries possible. Several vitiligo-specific instruments were identified. The vitiligo Impact Scale (VIS) is an extensively validated vitiligo-specific HRQoL instrument with proposed minimal important change and clinical interpretation for VIS-22 scores. VIS-22 was developed for use in India, where there are some specific cultural beliefs concerning vitiligo. The EADV Task Force on QoL and Patient Oriented Outcomes recommends use of the DLQI and the Children's Dermatology Life Quality Index (CDLQI) as dermatology-specific instruments in vitiligo. There is a strong need for a valid (including cross-cultural validation) vitiligo-specific instrument that can be either a new instrument or the improvement of existing instruments. This validation must include the proof of responsiveness.",
keywords = "Child, Humans, Dermatology, Quality of Life, Surveys and Questionnaires, Venereology, Vitiligo/therapy",
author = "Chernyshov, {Pavel V} and Lucia Tomas-Aragones and Liana Manolache and Nives Pustisek and Salavastru, {Carmen Maria} and Marron, {Servando E} and Anthony Bewley and Ake Svensson and Fran{\c c}oise Poot and Alina Suru and Salek, {Sam S} and Matthias Augustin and Szepietowski, {Jacek С} and Dimitra Koumaki and Katoulis, {Alexander C} and Francesca Sampogna and Damiano Abeni and Linder, {Dennis Michael} and Reinhart Speeckaert and {van Geel}, Nanja and Julien Seneschal and Khaled Ezzedine and Finlay, {Andrew Y}",
note = "{\textcopyright} 2022 European Academy of Dermatology and Venereology.",
year = "2023",
month = jan,
doi = "10.1111/jdv.18593",
language = "English",
volume = "37",
pages = "21--31",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Quality of life measurement in vitiligo: Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts

AU - Chernyshov, Pavel V

AU - Tomas-Aragones, Lucia

AU - Manolache, Liana

AU - Pustisek, Nives

AU - Salavastru, Carmen Maria

AU - Marron, Servando E

AU - Bewley, Anthony

AU - Svensson, Ake

AU - Poot, Françoise

AU - Suru, Alina

AU - Salek, Sam S

AU - Augustin, Matthias

AU - Szepietowski, Jacek С

AU - Koumaki, Dimitra

AU - Katoulis, Alexander C

AU - Sampogna, Francesca

AU - Abeni, Damiano

AU - Linder, Dennis Michael

AU - Speeckaert, Reinhart

AU - van Geel, Nanja

AU - Seneschal, Julien

AU - Ezzedine, Khaled

AU - Finlay, Andrew Y

N1 - © 2022 European Academy of Dermatology and Venereology.

PY - 2023/1

Y1 - 2023/1

N2 - Members of the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient Oriented Outcomes reviewed the instruments available for health-related (HR) QoL assessment in vitiligo and together with external vitiligo experts (including representatives of the EADV Vitiligo Task Force) have made practical recommendations concerning the assessment of QoL in vitiligo patients. The Dermatology Life Quality Index (DLQI) was the most frequently used HRQoL instrument, making comparison of results between different countries possible. Several vitiligo-specific instruments were identified. The vitiligo Impact Scale (VIS) is an extensively validated vitiligo-specific HRQoL instrument with proposed minimal important change and clinical interpretation for VIS-22 scores. VIS-22 was developed for use in India, where there are some specific cultural beliefs concerning vitiligo. The EADV Task Force on QoL and Patient Oriented Outcomes recommends use of the DLQI and the Children's Dermatology Life Quality Index (CDLQI) as dermatology-specific instruments in vitiligo. There is a strong need for a valid (including cross-cultural validation) vitiligo-specific instrument that can be either a new instrument or the improvement of existing instruments. This validation must include the proof of responsiveness.

AB - Members of the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient Oriented Outcomes reviewed the instruments available for health-related (HR) QoL assessment in vitiligo and together with external vitiligo experts (including representatives of the EADV Vitiligo Task Force) have made practical recommendations concerning the assessment of QoL in vitiligo patients. The Dermatology Life Quality Index (DLQI) was the most frequently used HRQoL instrument, making comparison of results between different countries possible. Several vitiligo-specific instruments were identified. The vitiligo Impact Scale (VIS) is an extensively validated vitiligo-specific HRQoL instrument with proposed minimal important change and clinical interpretation for VIS-22 scores. VIS-22 was developed for use in India, where there are some specific cultural beliefs concerning vitiligo. The EADV Task Force on QoL and Patient Oriented Outcomes recommends use of the DLQI and the Children's Dermatology Life Quality Index (CDLQI) as dermatology-specific instruments in vitiligo. There is a strong need for a valid (including cross-cultural validation) vitiligo-specific instrument that can be either a new instrument or the improvement of existing instruments. This validation must include the proof of responsiveness.

KW - Child

KW - Humans

KW - Dermatology

KW - Quality of Life

KW - Surveys and Questionnaires

KW - Venereology

KW - Vitiligo/therapy

U2 - 10.1111/jdv.18593

DO - 10.1111/jdv.18593

M3 - Guideline, recommendation, statement

C2 - 36259656

VL - 37

SP - 21

EP - 31

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 1

ER -